Titlebook: Resistance to Aromatase Inhibitors in Breast Cancer; Alexey Larionov Book 2015 Springer International Publishing Switzerland 2015 aromatas

變化

放逐某人

2196-5501 ological resistance and potential biomarkers that recognize Aromatase Inhibitors (AIs) treat postmenopausal estrogen receptor positive tumours, which constitute the majority of breast cancer patients. This comprehensive volume brings together the current knowledge from different relevant areas, incl

調(diào)整校對(duì)

Clinical Use of Aromatase Inhibitors in Breast Cancer: History and Present,t-menopausal women the treatment is now much simpler with the advent of highly specific and effective aromatase inhibitors. This chapter will summarise the history of endocrine deprivation therapy in post-menopausal women with breast cancer, and outline where these drugs are used today, what is know

travail

craving

Structure, Function and Inhibition of Aromatase,omatase has revealed an androgen-specific active site. The structural insights have been utilized in the investigation of its transmembrane integration, roles of critical residues, reaction mechanism, implications of motion and flexibility on its function, ligand-binding interactions, and oligomeric

Orthodontics

Germinate

neolith

婚姻生活

Ligand-Independent Signalling Through Estrogen Receptor Pathways in Breast Cancer,ism by which tumour cells can evade AI therapy is to find alternative ways to activate the estrogen receptor in the absence of ligand. Here we discuss mechanisms of ligand-independent receptor activation including growth factor cross talk, kinase induced phosphorylation, the involvement of co-factor

INCH

Chromatin and Epigenetic Determinants of Resistance to Aromatase Inhibitors,ibility and epigenetic modifications play a crucial role in regulating gene expression in normal development and contribute to aberrant transcription commonly found in malignant cells. In this chapter we will discuss the latest research findings linking AI resistance to epigenetics. Initially we wil